Blue Water Vaccines Announces Corporate Name Change to Blue Water Biotech in Connection with Transition into Commercial-Stage Biotechnology Company
April 24 2023 - 8:00AM
Blue Water Vaccines Inc. (“Blue Water” or the “Company”), a
biopharmaceutical company developing transformational therapies to
address significant global health challenges, today announced that
it has changed its corporate name to Blue Water Biotech, Inc. The
corporate name change follows the Company’s recent acquisition of
ENTADFI®, an FDA-approved treatment for benign prostatic
hyperplasia (“BPH”), which has commenced Blue Water’s transition
into a commercial-stage biotechnology company.
“Our recent purchase of ENTADFI® is transforming Blue Water into
a commercial-stage biotechnology company and this name change is an
exciting reflection of that progress,” said Joseph Hernandez,
Chairman and Chief Executive Officer of Blue Water. “With ENTADFI®,
we are building a nimble and effective commercial operation that
can be leveraged for our current pipeline or future acquired
assets. Over the last few months, we have carefully developed a
strong and experienced management team to lead us as we navigate
this transition, and we are confident that the future of Blue Water
and this product are very bright.”
Blue Water’s commercial team is highlighted by Senior Vice
President of Marketing and Business Development, Frank Jaeger, a
seasoned marketing and business development executive with
extensive experience in the men’s health sector. Mr. Jaeger’s
background and knowledge, along with Blue Water’s accomplished
management team, will lead the official launch of ENTADFI® to
generate revenue and impact within the BPH space.
In addition to ENTADFI® for the treatment of BPH, Blue Water is
developing multiple vaccines to prevent infectious diseases with
high unmet need. BWV-201, Blue Water’s lead vaccine candidate, is a
live attenuated, intranasally delivered, serotype independent
Streptococcus pneumoniae vaccine targeting acute otitis media and
pneumococcal pneumonia. Additionally, Blue Water is developing a
universal influenza vaccine and multiple vaccines using its
virus-like particle technology, including Marburg virus disease.
Finally, Blue Water is developing a live attenuated, orally
delivered Chlamydia vaccine developed with The University of Texas
Health Science Center at San Antonio.
Blue Water’s common stock will continue to trade under the
ticker symbol NASDAQ: BWV.
About ENTADFI®
ENTADFI® is an oral, once daily treatment for benign prostatic
hyperplasia ("BPH") that combines finasteride, a 5α-reductase
inhibitor, and tadalafil, a phosphodiesterase 5 (PDE5) inhibitor,
offering a more effective treatment option compared to other
available therapies. Clinical trials have shown that ENTADFI® is
more effective in treating BPH symptoms, including urinary
frequency, urgency, weak stream, and difficulty initiating or
maintaining urination, compared to finasteride monotherapy.
Additionally, ENTADFI® has demonstrated a favorable safety profile,
with fewer adverse sexual side effects compared to finasteride.
ENTADFI® reduces potential for adverse sexual side effects, making
it a preferred choice for men seeking relief from BPH symptoms
without compromising their sexual health. ENTADFI® has received FDA
approval for the indication of initiating treatment of the signs
and symptoms of BPH in men with an enlarged prostate for up to 26
weeks. More information about BPH and full ENTADFI® prescribing
information can be found on the product website at
https://entadfipatient.com/.
About Blue Water Biotech
Blue Water Biotech, Inc. is a biotechnology company focused on
developing transformational therapies to address significant health
challenges globally. Headquartered in Cincinnati, OH, the Company
holds the rights to proprietary technology developed at the
University of Oxford, Cincinnati Children’s Hospital Medical
Center, St. Jude Children’s Hospital, and The University of Texas
Health Science Center at San Antonio. Blue Water is developing a
Streptococcus pneumoniae vaccine candidate, designed to
specifically prevent highly infectious middle ear infections, known
as acute otitis media (AOM), in children, and prevention of
pneumonia in the elderly. The Company is also developing a
universal flu vaccine that will provide protection from all
virulent strains in addition to licensing a novel norovirus (NoV)
S&P nanoparticle versatile virus-like particle (VLP) vaccine
platform from Cincinnati Children’s to develop vaccines for
multiple infectious diseases, including Marburg and monkeypox,
among others. Additionally, the Company is developing a Chlamydia
vaccine candidate with UT Health Science Center San Antonio to
prevent infection and reduce the need for antibiotic treatment
associated with contracting Chlamydia disease. Outside of its
vaccine franchise, Blue Water owns ENTADFI®, an FDA-approved, once
daily pill that combines finasteride and tadalafil for the
treatment of benign prostatic hyperplasia. This combination allows
men to receive treatment for their symptoms of BPH without the
negative sexual side effects typically seen in patients on
finasteride alone. For more information about Blue Water, visit
www.bluewatervaccines.com.
Forward-Looking Statements
Certain statements in this press release are forward-looking
within the meaning of the Private Securities Litigation Reform Act
of 1995. These statements may be identified by the use of
forward-looking words such as “anticipate,” “believe,” “forecast,”
“estimate,” “expect,” and “intend,” among others. These
forward-looking statements are based on Blue Water’s current
expectations and actual results could differ materially. There are
a number of factors that could cause actual events to differ
materially from those indicated by such forward-looking statements.
These factors include, but are not limited to, risks related to
Blue Water’s ability to realize the benefits of its acquisition of
ENTADFI®, risks related to BWV’s ability to expand its business
scope and its ability to commercialize ENTADFI®, risks related to
the development of Blue Water’s vaccine candidates; the failure to
obtain FDA clearances or approvals and noncompliance with FDA
regulations; delays and uncertainties caused by the global COVID-19
pandemic; risks related to the timing and progress of clinical
development of our product candidates; our need for additional
financing; uncertainties of patent protection and litigation;
uncertainties of government or third party payor reimbursement;
limited research and development efforts and dependence upon third
parties; and substantial competition. As with any vaccine under
development, there are significant risks in the development,
regulatory approval and commercialization of new products. Blue
Water does not undertake an obligation to update or revise any
forward-looking statement. Investors should read the risk factors
set forth in Blue Water’s Annual Report on Form 10-K, filed with
the Securities and Exchange Commission (the “SEC”) on March 9, 2023
and periodic reports filed with the SEC on or after the date
thereof. All of Blue Water’s forward-looking statements are
expressly qualified by all such risk factors and other cautionary
statements. The information set forth herein speaks only as of the
date thereof.
Media Contact Information:Blue Water Media
RelationsTelephone: (646) 942-5591 Email:
Nic.Johnson@russopartnersllc.com
Investor Contact Information:Blue Water Investor RelationsEmail:
investors@bluewatervaccines.com
Blue Water Biotech (NASDAQ:BWV)
Historical Stock Chart
From Jun 2024 to Jul 2024
Blue Water Biotech (NASDAQ:BWV)
Historical Stock Chart
From Jul 2023 to Jul 2024